WGA5
GenomePlex® Tissue Whole Genome Amplification Kit
Amplify DNA from fresh, frozen or FFPE tissue
shipped in
wet ice
storage temp.
−20°C
General description
GenomePlex Tissue Whole Genome Amplification Kit utilizes a proprietary technology based on random fragmentation of genomic DNA and conversion of the resulting small fragments to PCR-amplifiable library molecules flanked by universal priming sites. WGA is achieved by PCR amplification of the library molecules using universal oligonucleotide primers.
Legal Information
Use of this product is covered by one or more of the following US patents and corresponding patent claims outside the US: 5,789,224, 5,618,711, 6,127,155 and claims outside the US corresponding to expired US Patent No. 5,079,352. The purchase of this product includes a limited, non-transferable immunity from suit under the foregoing patent claims for using only this amount of product for the purchaser′s own internal research. No right under any other patent claim, no right to perform any patented method, and no right to perform commercial services of any kind, including without limitation reporting the results of purchaser′s activities for a fee or other commercial consideration, is conveyed expressly, by implication, or by estoppel. This product is for research use only. Diagnostic uses under Roche patents require a separate license from Roche. Further information on purchasing licenses may be obtained by contacting the Director of Licensing, Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404, USA.
GenomePlex is a registered trademark of Takara Bio USA, Inc.
Kit Components Also Available Separately
Product No.
Description
SDS
- P4850Proteinase K from Tritirachium album, buffered aqueous glycerol solution, Molecular Biology, ≥800 units/mLSDS
Signal Word
Danger
Hazard Statements
Precautionary Statements
Hazard Classifications
Aquatic Chronic 3 - Eye Irrit. 2 - Resp. Sens. 1
Storage Class Code
10 - Combustible liquids
Regulatory Information
新产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Inga-Marie Schaefer et al.
Nature communications, 8, 14674-14674 (2017-03-09)
KIT, PDGFRA, NF1 and SDH mutations are alternate initiating events, fostering hyperplasia in gastrointestinal stromal tumours (GISTs), and additional genetic alterations are required for progression to malignancy. The most frequent secondary alteration, demonstrated in ∼70% of GISTs, is chromosome 14q
A multiplex PCR predictor. for aCGH success of FFPE samples.
Van Beers E.H., et al.
British Journal of Cancer, 94, 333-337 (2005)
X Xiong et al.
Oncogenesis, 1, e26-e26 (2012-01-01)
Prostate cancer is one of the leading causes of cancer-related deaths in the United States and a leading diagnosed non-skin cancer in American men. Genetic mutations underlying prostate tumorigenesis include alterations of tumor suppressor genes. We tested the tumor suppressor
Mythily Srinivasan et al.
The American journal of pathology, 161(6), 1961-1971 (2002-12-06)
Clinical and molecular medicines are undergoing a revolution based on the accelerated advances in biotechnology such as DNA microarrays and proteomics. Answers to fundamental questions such as how does the DNA sequence differ between individuals and what makes one individual
Nazif Alic et al.
Molecular systems biology, 7, 502-502 (2011-06-23)
FoxO transcription factors, inhibited by insulin/insulin-like growth factor signalling (IIS), are crucial players in numerous organismal processes including lifespan. Using genomic tools, we uncover over 700 direct dFOXO targets in adult female Drosophila. dFOXO is directly required for transcription of
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service